[go: up one dir, main page]

ES2110260T3 - Androstenonas. - Google Patents

Androstenonas.

Info

Publication number
ES2110260T3
ES2110260T3 ES94928605T ES94928605T ES2110260T3 ES 2110260 T3 ES2110260 T3 ES 2110260T3 ES 94928605 T ES94928605 T ES 94928605T ES 94928605 T ES94928605 T ES 94928605T ES 2110260 T3 ES2110260 T3 ES 2110260T3
Authority
ES
Spain
Prior art keywords
methyl
hydrogen
androstenonas
link
androgens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94928605T
Other languages
English (en)
Inventor
Kenneth W Batchelor
Stephen V Frye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Application granted granted Critical
Publication of ES2110260T3 publication Critical patent/ES2110260T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/14—Benz[f]indenes; Hydrogenated benz[f]indenes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA (I), EN DONDE LOS CARBONOS 1 Y 2 ESTAN UNIDOS BIEN POR UN ENLACE SIMPLE O BIEN POR UN ENLACE DOBLE; R1 ES HIDROGENO O METILO; R2 ES HIDROGENO O METILO; R3 ES (A) O (B) EN DONDE X, W, Z, R4, R5, R6, R7 Y R8 SON DIFERENTES GRUPOS, TAMBIEN SE PRESENTAN LOS SOLVATOS FARMACOLOGICAMENTE ACEPTABLES DE LOS MISMOS Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES INTERMEDIADAS Y SENSIBLES A LOS ANDROGENOS.
ES94928605T 1993-09-17 1994-09-16 Androstenonas. Expired - Lifetime ES2110260T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12328093A 1993-09-17 1993-09-17
US13651593A 1993-10-12 1993-10-12

Publications (1)

Publication Number Publication Date
ES2110260T3 true ES2110260T3 (es) 1998-02-01

Family

ID=26821398

Family Applications (2)

Application Number Title Priority Date Filing Date
ES97200658T Expired - Lifetime ES2140181T3 (es) 1993-09-17 1994-09-16 Androstenonas.
ES94928605T Expired - Lifetime ES2110260T3 (es) 1993-09-17 1994-09-16 Androstenonas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES97200658T Expired - Lifetime ES2140181T3 (es) 1993-09-17 1994-09-16 Androstenonas.

Country Status (19)

Country Link
US (1) US5977126A (es)
EP (2) EP0783001B1 (es)
CN (1) CN1041939C (es)
AT (2) ATE186733T1 (es)
AU (1) AU685167B2 (es)
CA (3) CA2478971C (es)
DE (2) DE69421726T2 (es)
DK (2) DK0783001T3 (es)
ES (2) ES2140181T3 (es)
FI (1) FI961232L (es)
GR (2) GR3025717T3 (es)
HU (1) HUT74445A (es)
IL (1) IL110979A (es)
IS (1) IS1726B (es)
NO (1) NO306510B1 (es)
NZ (1) NZ274059A (es)
RU (1) RU2144037C1 (es)
TW (1) TW408127B (es)
WO (1) WO1995007926A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US6001844A (en) * 1995-09-15 1999-12-14 Merck & Co., Inc. 4-Azasteroids for treatment of hyperandrogenic conditions
US5935968A (en) 1997-03-17 1999-08-10 Merck & Co., Inc. Methods for treating polycystic ovary syndrome
GB9717428D0 (en) * 1997-08-19 1997-10-22 Glaxo Group Ltd Pharmaceutical composition
GB9717444D0 (en) * 1997-08-19 1997-10-22 Glaxo Group Ltd Pharmaceutical composition
EP1228083A2 (en) * 1999-09-30 2002-08-07 Hollis-Eden Pharmaceuticals Inc. Therapeutic treatment of androgen receptor driven conditions
NZ526216A (en) 2000-11-03 2005-02-25 Univ Manchester Selective glucocorticoid receptor agonists
GB0026876D0 (en) * 2000-11-03 2000-12-20 Glaxo Group Ltd Process
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
WO2003029268A1 (en) * 2001-10-03 2003-04-10 Merck & Co., Inc. Androstane 17-beta-carboxamides as androgen receptor modulators
CA2478186C (en) * 2002-03-13 2011-08-23 Merck & Co., Inc. Fluorinated 4-azasteroid derivatives as androgen receptor modulators
US20050131005A1 (en) * 2002-04-30 2005-06-16 Jiabing Wang 4-azasteroid derivatives as androgen receptor modulators
CU23256A1 (es) * 2003-03-20 2008-01-24 Dalmer Lab Sa EXTRACTO OBTENIDO A PARTIR DE FRUTOS DE ROYSTONEA REGIA UTILIZADO CONTRA LA HIPERPLASIA PROSTáTICA Y LA PROSTATITIS
EP1742631A4 (en) * 2004-04-28 2009-11-11 Merck & Co Inc FLUORATED 4-AZASTEROIDS AS ANDROGEN RECEPTOR MODULATORS
HU230730B1 (hu) 2011-06-30 2017-12-28 Richter Gedeon Nyrt Eljárás (5alfa,17béta)-N-[2,5-bisz-(trifluormetil)-fenil]-3-oxo-4-aza-5-androszt-1-én-17-karbonsavamid előállítására
CN102532236B (zh) * 2012-01-05 2014-04-16 中国药科大学 甾体类5α-还原酶抑制剂、其制备方法及其医药用途
CN103554213A (zh) * 2012-01-05 2014-02-05 中国药科大学 4-氧杂-雄甾-3-酮-17β-酰胺类衍生物、其制备方法及其医药用途
CN103570796A (zh) * 2012-07-24 2014-02-12 重庆医药工业研究院有限责任公司 一种度他雄胺ⅰ型晶的制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
US5049562A (en) * 1984-02-27 1991-09-17 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
US4845104A (en) * 1986-11-20 1989-07-04 Merck & Co., Inc. Oxidized analogs of 17β-N-monosubstituted-carbamoyl-4-aza-5-α-androstan-3-ones
DE3780778T2 (de) * 1986-11-20 1993-01-14 Merck & Co Inc Topisches arzneimittel enthaltend 17-beta-methoxy-carbonyl-4-methyl-4-aza-5-alpha-androst-1-en-3-one.
US4888336A (en) * 1987-01-28 1989-12-19 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
EP0285383B1 (en) * 1987-04-03 1994-03-16 Merck & Co. Inc. Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones
ZA883034B (en) * 1987-04-29 1989-03-29 Smithkline Beckman Corp Steroid 5-alpha-reductase inhibitors
US5084574A (en) * 1988-04-18 1992-01-28 Merck & Co., Inc. Dehydrogenation process
CA2023157A1 (en) * 1989-08-21 1991-02-22 Gary H. Rasmusson 17 beta-acyl-4-aza-5 alpha-androst-1-ene-3-ones as 5 alpha-reductase inhibitors
US5021575A (en) * 1989-11-13 1991-06-04 Merck & Co., Inc. Method for introducing a 1,2 double bond into azasteroids
EP0462664A3 (en) * 1990-06-20 1992-11-25 Merck & Co. Inc. Specific 17beta-thiobenzoyl-4-aza-5alpha-androst-1-en-3-ones as antiandrogenic agents
US5098908A (en) * 1990-06-20 1992-03-24 Merck & Co., Inc. 17β-hydroxybenzoyl-4-aza-5α-androst-1-en-3-ones as testosterone reductase inhibitors
EP0462662A3 (en) * 1990-06-20 1992-08-19 Merck & Co. Inc. 17beta-n-monosubstituted adamantyl/norbornanyl carbamoyl-4-aza-5alpha-androst-1-en-3-ones and androstan-3-ones
IE76452B1 (en) * 1990-10-29 1997-10-22 Sankyo Co Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
IL101245A0 (en) * 1991-03-20 1992-11-15 Merck & Co Inc Pharmaceutical compositions for the treatment of prostatic cancer
IL101243A (en) * 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
WO1992018132A1 (en) * 1991-04-17 1992-10-29 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives
EP0547687A1 (en) * 1991-12-18 1993-06-23 Merck & Co. Inc. 17B-N-Substituted adamantyl/norbonanyl carbamoyl-4-aza-5a-and-rost-1-en-3-ones and androstan-3 ones
JP3164389B2 (ja) * 1991-12-25 2001-05-08 三共株式会社 ４−アザステロイド類
US5215894A (en) * 1992-02-25 1993-06-01 Merck & Co., Inc. Biological process for producing 17β-N-monosubstituted carbamoyl-11-oxo-4-aza-5-α-androst-3-one testosterone-5-α reductase inhibitors
US5710275A (en) * 1992-05-20 1998-01-20 Merck & Co., Inc. 7β-substituted-4-aza-5α-androstan-3-ones as 5α-reductase inhibitors
AU674145B2 (en) * 1992-05-20 1996-12-12 Merck & Co., Inc. New 17-ester, amide, and ketone derivatives of 3-oxo-4-azasteroids as 5a-reductase inhibitors
AU676478B2 (en) * 1992-05-20 1997-03-13 Merck & Co., Inc. New delta-17 and delta-20 olefinic and saturated 17beta- substituted-4-aza-5alpha-androstan-3-ones as 5alpha- reductase inhibitors
CA2135173A1 (en) * 1992-05-20 1993-11-25 Bruce E. Witzel Ester derivatives of 4-aza-steroids
WO1993023038A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. 17-AMINO SUBSTITUTED 4-AZASTEROID 5α-REDUCTASE INHIBITORS
RU94046044A (ru) * 1992-05-20 1996-10-10 Мерк Энд Ко. Новые 7 бета -замещенные 4-аза- 5 альфа -холестан-оны в качестве ингибиторов 5 альфа -редуктазы, фармацевтическая композиция на их основе, способ ее получения
AU4251993A (en) * 1992-05-20 1993-12-13 Merck & Co., Inc. Substituted 4-aza-5A-androstan-ones as 5A-reductase inhibitors
WO1993023040A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. 17-ethers and thioethers of 4-aza-steroids
ES2149208T3 (es) * 1992-05-20 2000-11-01 Merck & Co Inc Inhibidores 4-azaesteroides de 5-alfa-reductasa.
AU4258493A (en) * 1992-05-21 1993-12-13 Endorecherche Inc. Inhibitors of testosterone 5alpha-reductase activity
GB9210880D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Corp Compounds
DE69329933T2 (de) * 1992-10-06 2001-07-19 Merck & Co., Inc. 17-beta-carboxanilid derivate von 4-aza-5-alpha-androstan-3-one als 5-alpha-reduktase-hemmende arzneimittel
US5468860A (en) * 1992-11-19 1995-11-21 Merck & Co., Inc. New finasteride processes
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5512555A (en) * 1994-07-21 1996-04-30 Merck & Co., Inc. Method of treating sweat-related conditions using finasteride, epristeride and a cholestan-3-one

Also Published As

Publication number Publication date
DK0783001T3 (da) 2000-04-10
CN1134155A (zh) 1996-10-23
ES2140181T3 (es) 2000-02-16
AU685167B2 (en) 1998-01-15
AU7798094A (en) 1995-04-03
FI961232A7 (fi) 1996-03-15
US5977126A (en) 1999-11-02
DE69421726D1 (de) 1999-12-23
EP0783001A1 (en) 1997-07-09
EP0719277A1 (en) 1996-07-03
IS4206A (is) 1995-03-18
RU2144037C1 (ru) 2000-01-10
DE69407422T2 (de) 1998-04-09
CA2449679A1 (en) 1995-03-23
GR3032198T3 (en) 2000-04-27
NO961085D0 (no) 1996-03-15
CA2478971C (en) 2007-10-23
NZ274059A (en) 1997-12-19
CN1041939C (zh) 1999-02-03
NO306510B1 (no) 1999-11-15
GR3025717T3 (en) 1998-03-31
TW408127B (en) 2000-10-11
HUT74445A (en) 1996-12-30
WO1995007926A1 (en) 1995-03-23
CA2171329A1 (en) 1995-03-23
FI961232A0 (fi) 1996-03-15
EP0719277B1 (en) 1997-12-17
DK0719277T3 (da) 1998-08-24
CA2171329C (en) 2004-11-23
IS1726B (is) 1999-09-06
HU9600643D0 (en) 1996-05-28
DE69421726T2 (de) 2000-06-29
IL110979A0 (en) 1994-11-28
FI961232L (fi) 1996-03-15
ATE161268T1 (de) 1998-01-15
IL110979A (en) 1999-08-17
DE69407422D1 (en) 1998-01-29
CA2478971A1 (en) 1995-03-23
ATE186733T1 (de) 1999-12-15
NO961085L (no) 1996-04-22
EP0783001B1 (en) 1999-11-17
CA2449679C (en) 2007-10-23

Similar Documents

Publication Publication Date Title
ES2110260T3 (es) Androstenonas.
MX9102407A (es) 4 arilpiperazinas y 4-arilpiperidinas novedosas.
ES2062374T3 (es) Heteroarilpiperazinas, agentes antipsicoticos.
ES2194314T3 (es) Derivados de benzopirano sustituidos para el tratamiento de inflamaciones.
ES2127946T3 (es) Antagonistas de neurocinina diazabiciclica.
ES2188584T3 (es) Derivados heterociclicos de amina.
DE69616480D1 (de) Piperidinderivate als neurokininantagonisten
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
AR003955A1 (es) Derivados de n-(indol-2-carbonil)-glicinamidas, procedimiento para su obtencion y composiciones que los contienen.
ES2189235T3 (es) 6-fenilfenantridinas sustituidas.
ES2163638T3 (es) Nuevas n-(1-alquil-5-fenil-2,3,4,5-tetrahidro-1h-benzo(b)(1,5)diacepin-3-il)acetamidas.
PT1178045E (pt) Derivados de azaindole-etilamina como agentes de ligacao de receptores de acetilcolina nicotinicos
PE29798A1 (es) Acetidinas
ES2123873T3 (es) Pirrolocarbazol.
ES2165395T3 (es) Oxazolinas y tiazolinas artropodicidas.
ES2193241T3 (es) Nuevas n-2-oxo2.3.4.5-tetrajodrp-1h-1,5-benzodiazepin-3-il)-3-amidas.
ES2151168T3 (es) N-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas.
ES2101073T3 (es) Nuevos aza-androstano-derivados 17-beta-substituidos.
ES2107035T3 (es) Derivados de 3-azabiciclo(3.2.0)heptano n-substituidos como neurolepticos etc..
ES2060818T3 (es) Derivados de indol, benzofurano y benzotiofeno sustituidos como inhibidores de la 5-lipooxigenasa.
ES2171911T3 (es) Poliaminas conformacionalmente restringidas y su uso como agentes antineoplasicos.
BR9914255A (pt) Derivados de indolina como agentes de proteção de luz
MX9700807A (es) Derivados de 3-azabiciclo (3.2.0)heptano n-sustituidos utiles como neurolepticos.
YU44301A (sh) 5ht1 antagonisti za antidepresantnu terapiju
BR9708418A (pt) Amino-e trifenil-s-triazinas hodroxissubstituídas como estabilizadores

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 719277

Country of ref document: ES